

Michelle A Rudek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/353997/publications.pdf>

Version: 2024-02-01

63
papers

2,607
citations

236925

25
h-index

197818

49
g-index

66
all docs

66
docs citations

66
times ranked

5404
citing authors

#	ARTICLE	IF	CITATIONS
1	A Targeting Modality for Destruction of RNA Polymerase I that Possesses Anticancer Activity. <i>Cancer Cell</i> , 2014, 25, 77-90.	16.8	231
2	Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2042-2048.	2.0	219
3	Targeting <i>DDX3</i> with a small molecule inhibitor for lung cancer therapy. <i>EMBO Molecular Medicine</i> , 2015, 7, 648-669.	6.9	189
4	Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. <i>Nature Communications</i> , 2018, 9, 53.	12.8	175
5	Use of antineoplastic agents in patients with cancer who have HIV/AIDS. <i>Lancet Oncology</i> , The, 2011, 12, 905-912.	10.7	137
6	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology's Friends of Cancer Research HIV Working Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 3774-3780.	1.6	114
7	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacytidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. <i>Clinical Cancer Research</i> , 2017, 23, 2691-2701.	7.0	106
8	Pharmacokinetics of 5-Azacytidine Administered With Phenylbutyrate in Patients With Refractory Solid Tumors or Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2005, 23, 3906-3911.	1.6	98
9	Entinostat: a promising treatment option for patients with advanced breast cancer. <i>Future Oncology</i> , 2017, 13, 1137-1148.	2.4	94
10	A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. <i>Prostate</i> , 2015, 75, 1518-1525.	2.3	88
11	Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432. <i>Clinical Cancer Research</i> , 2012, 18, 2954-2963.	7.0	68
12	Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model. <i>Clinical Cancer Research</i> , 2015, 21, 3462-3470.	7.0	66
13	Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2013, 19, 3631-3639.	7.0	59
14	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 697-706.	7.0	56
15	The HDAC3-SMARCA4-miR-27a axis promotes expression of the <i>PAX3:FOXO1</i> fusion oncogene in rhabdomyosarcoma. <i>Science Signaling</i> , 2018, 11, .	3.6	51
16	Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 3033-3038.	2.3	46
17	HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	44
18	Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients. <i>Investigational New Drugs</i> , 2012, 30, 2096-2102.	2.6	42

#	ARTICLE	IF	CITATIONS
19	Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma. <i>Neuro-Oncology</i> , 2015, 17, 70-80.	1.2	42
20	The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. <i>Journal of Neuro-Oncology</i> , 2016, 126, 433-439.	2.9	41
21	Metformin Protects Cells from Mutant Huntingtin Toxicity Through Activation of AMPK and Modulation of Mitochondrial Dynamics. <i>NeuroMolecular Medicine</i> , 2016, 18, 581-592.	3.4	40
22	Ezrin Inhibition Up-regulates Stress Response Gene Expression. <i>Journal of Biological Chemistry</i> , 2016, 291, 13257-13270.	3.4	40
23	Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies. <i>Cancer Research</i> , 2017, 77, 5554-5563.	0.9	36
24	A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 300-306.	2.0	36
25	Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted <i>in vivo</i> , and synergized with antileukemic drugs. <i>Oncotarget</i> , 2016, 7, 7268-7279.	1.8	28
26	A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. <i>Cancer</i> , 2014, 120, 1194-1202.	4.1	26
27	Shorter-course treatment for <i>Mycobacterium ulcerans</i> disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006728.	3.0	26
28	Temozolomide in Patients with Advanced Cancer: Phase I and Pharmacokinetic Study. <i>Pharmacotherapy</i> , 2004, 24, 16-25.	2.6	25
29	Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma. <i>Aids</i> , 2018, 32, 605-611.	2.2	24
30	The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects. <i>Clinical Cancer Research</i> , 2016, 22, 5472-5479.	7.0	23
31	A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. <i>Clinical and Translational Science</i> , 2020, 13, 1178-1188.	3.1	23
32	Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034. <i>Leukemia and Lymphoma</i> , 2018, 59, 1851-1860.	1.3	21
33	A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. <i>Oncologist</i> , 2017, 22, 505-e49.	3.7	20
34	Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy. <i>Oncotarget</i> , 2017, 8, 104182-104192.	1.8	20
35	Increased uptake of doxorubicin by cells undergoing heat stress does not explain its synergistic cytotoxicity with hyperthermia. <i>International Journal of Hyperthermia</i> , 2019, 36, 711-719.	2.5	20
36	Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2011, 105, 375-381.	2.9	18

#	ARTICLE	IF	CITATIONS
37	Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). <i>Clinical Cancer Research</i> , 2021, 27, 5828-5837.	7.0	18
38	A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 5475-5484.	7.0	17
39	A phase 1 trial of the oral DNA methyltransferase inhibitor CCâ€486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. <i>Cancer</i> , 2019, 125, 2837-2845.	4.1	17
40	Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposureâ€FLT3 Relationship. <i>Clinical and Translational Science</i> , 2018, 11, 435-443.	3.1	15
41	A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007, 43, 784-787.	2.8	14
42	Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids. <i>Leukemia</i> , 2020, 34, 3077-3081.	7.2	14
43	Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrett's Esophagus to Invasive Esophageal Adenocarcinoma. <i>Annals of Surgery</i> , 2021, 273, e206-e213.	4.2	14
44	Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa154.	0.7	13
45	Simultaneous quantitative determination of 5-aza-2â€2-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1022, 38-45.	2.3	11
46	Safety and Preliminary Efficacy of Vorinostat WithÂR-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 180-190.e2.	0.4	11
47	A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 53, 54-59.	1.5	10
48	Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. <i>European Radiology</i> , 2021, 31, 3002-3014.	4.5	10
49	Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax. <i>Blood Advances</i> , 2021, 5, 711-724.	5.2	10
50	High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review. <i>Cancer Treatment Reviews</i> , 2021, 97, 102171.	7.7	8
51	Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2020, 26, 5329-5337.	7.0	6
52	A Novel 2-Carbon-Linked Dimeric Artemisinin With Potent Antileukemic Activity and Favorable Pharmacology. <i>Frontiers in Oncology</i> , 2021, 11, 790037.	2.8	5
53	A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 37, 751-756.	2.8	4
54	Exosome-Encased Nucleic Acid Scaffold Chemotherapeutic Agents for Superior Anti-Tumor and Anti-Angiogenesis Activity. <i>ACS Bio & Med Chem Au</i> , 2022, 2, 140-149.	3.7	4

#	ARTICLE	IF	CITATIONS
55	A method for determination of dimethyl benzoylphenyl urea(BPU) in human plasma by using LC/UV. Biomedical Chromatography, 2004, 18, 282-287.	1.7	3
56	Clonidine for sedation in infants during therapeutic hypothermia with neonatal encephalopathy: pilot study. Journal of Perinatology, 2021, , .	2.0	3
57	Serum Concentrations of Losartan Metabolites Correlate With Improved Physical Function in a Pilot Study of Prefrail Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 2356-2366.	3.6	3
58	Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study. Oncologist, 2022, 27, 623-e624.	3.7	2
59	Successful gene therapy requires targeting the vast majority of cancer cells. Cancer Biology and Therapy, 2020, 21, 946-953.	3.4	1
60	Validation of a rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of vistusertib. Journal of Pharmaceutical and Biomedical Analysis, 2022, 208, 114436.	2.8	1
61	Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of navitoclax. Biomedical Chromatography, 2021, , e5289.	1.7	1
62	For HIPEC, synergistic effects of hyperthermia and doxorubicin are optimal when simultaneously combined. International Journal of Hyperthermia, 2020, 37, 346-348.	2.5	0
63	Quantitation of terameprocol in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2022, 209, 114525.	2.8	0